Search

Displaying results 4921 - 4930 of 10000 in total
  1. Drug

    Etirinotecan pegol

    go.drugbank.com/drugs/DB14951
    Investigational

    Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).

    Categories: Topoisomerase II Inhibitors
  2. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  3. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  4. Drug

    Cefadroxil

    go.drugbank.com/drugs/DB01140
    ApprovedInvestigationalVet approvedWithdrawn

    Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

    Products: CEFADROXIL 1A PHARMA1000MG, CEFADROXILO 250MG/5ML POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL
  5. Drug

    LAX-101

    go.drugbank.com/drugs/DB05301
    Investigational

    The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.

  6. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. … Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.

  7. Drug

    Sermorelin

    go.drugbank.com/drugs/DB00010
    ApprovedWithdrawn

    Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing

  8. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  9. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. … It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  10. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Synonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide